Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Current Deferred Revenue (2016 - 2020)

Aytu Biopharma (AYTU) has disclosed Current Deferred Revenue for 6 consecutive years, with $475680.0 as the latest value for Q4 2020.

  • Quarterly Current Deferred Revenue changed N/A to $475680.0 in Q4 2020 from the year-ago period, while the trailing twelve-month figure was $475680.0 through Dec 2020, changed N/A year-over-year, with the annual reading at $339336.0 for FY2020, N/A changed from the prior year.
  • Current Deferred Revenue for Q4 2020 was $475680.0 at Aytu Biopharma, up from $232576.0 in the prior quarter.
  • The five-year high for Current Deferred Revenue was $475680.0 in Q4 2020, with the low at $1450.0 in Q2 2018.
  • Average Current Deferred Revenue over 4 years is $145070.9, with a median of $13990.0 recorded in 2018.
  • The sharpest move saw Current Deferred Revenue soared 397.0% in 2016, then crashed 98.43% in 2017.
  • Over 4 years, Current Deferred Revenue stood at $426000.0 in 2016, then plummeted by 98.88% to $4787.0 in 2017, then surged by 192.25% to $13990.0 in 2018, then skyrocketed by 3300.14% to $475680.0 in 2020.
  • According to Business Quant data, Current Deferred Revenue over the past three periods came in at $475680.0, $232576.0, and $339336.0 for Q4 2020, Q3 2020, and Q2 2020 respectively.